Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice.